ArticleJournal of immunology (Baltimore, Md. : 1950)2018
Immunoregulatory Activity of the Natural Product Laminarin Varies Widely as a Result of Its Physical Properties.
Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 83 citations in OpenAlex.
- Loss of Fgr41 inInfection and immunity · 2026Article
- Natural polysaccharides as immunometabolic modulators in metabolic diseases: mechanisms and translational challenges.Frontiers in immunology · 2026Review
- Beyond Nutrition: The Therapeutic Promise of Seaweed-Derived Polysaccharides Against Bacterial and Viral Threats.Marine drugs · 2025Review
- Fungal β-Glucans Shape Innate Immune Responses in Human Peripheral Blood Mononuclear Cells (PBMCs): An In Vitro Study on PRR Regulation, Cytokine Expression, and Oxidative Balance.International journal of molecular sciences · 2025Article
- Cell walls of filamentous fungi - challenges and opportunities for biotechnology.Applied microbiology and biotechnology · 2025Review
- Advancements in the Extraction, Characterization, and Bioactive Potential of Laminaran: A Review.Foods (Basel, Switzerland) · 2025Review
- Laminarin Alleviates Acute Lung Injury Induced by LPS Through Inhibition of M1 Macrophage Polarisation.Journal of cellular and molecular medicine · 2025Article
- Dectin-1 stimulating β-glucans inhibit Chlamydia infections both in vitro and in vivo.Pathogens and disease · 2025Article
- Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota.Frontiers in cellular and infection microbiology · 2025Review
- Candida albicans N-Linked Mannans Potentiate the Induction of Trained Immunity via Dectin-2.The Journal of infectious diseases · 2024Article
- Characterization of the Immune-Modulating Properties of Different β-Glucans on Myeloid Dendritic Cells.International journal of molecular sciences · 2024Article
- Article
- Recognition of yeast β-glucan particles triggers immunometabolic signaling required for trained immunity.iScience · 2024Article
- Heat-killediScience · 2024Article
- From algae to advancements: laminarin in biomedicine.RSC advances · 2024Review
- β-glucans fromFrontiers in nutrition · 2024Article
- Dectin-1 multimerization and signaling depends on fungal β-glucan structure and exposure.Biophysical journal · 2023Article
- In vitro anticancer potential of laminarin and fucoidan from Brown seaweeds.Scientific reports · 2023Article
- The Role of Seaweed Polysaccharides in Gastrointestinal Health: Protective Effect against Inflammatory Bowel Disease.Life (Basel, Switzerland) · 2023Review
- Differential Recognition of Clinically RelevantJournal of fungi (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Ligation of Dectin-1 by fungal glucans elicits a Th17 response that is necessary for clearing many fungal pathogens. Laminarin is a (1→3, 1→6)-β-glucan that is widely reported to be a Dectin-1 antagonist, however, there are reports that laminarin is also a Dectin-1 agonist. To address this controversy, we assessed the physical properties, structure, purity, Dectin-1 binding, and biological activity of five different laminarin preparations from three different commercial sources. The proton nuclear magnetic resonance analysis indicated that all of the preparations contained laminarin although their molecular mass varied considerably (4400-34,400 Da). Two of the laminarins contained substantial quantities of very low m.w. compounds, some of which were not laminarin. These low m.w. moieties could be significantly reduced by extensive dialysis. All of the laminarin preparations were bound by recombinant human Dectin-1 and mouse Dectin-1, but the affinity varied considerably, and binding affinity did not correlate with Dectin-1 agonism, antagonism, or potency. In both human and mouse cells, two laminarins were Dectin-1 antagonists and two were Dectin-1 agonists. The remaining laminarin was a Dectin-1 antagonist, but when the low m.w. moieties were removed, it became an agonist. We were able to identify a laminarin that is a Dectin-1 agonist and a laminarin that is Dectin-1 antagonist, both of which are relatively pure preparations. These laminarins may be useful in elucidating the structure and activity relationships of glucan/Dectin-1 interactions. Our data demonstrate that laminarin can be either a Dectin-1 antagonist or agonist, depending on the physicochemical properties, purity, and structure of the laminarin preparation employed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.